# Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers

> **NCT01741519** · PHASE1 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LDLL600
- **DRUG:** Brevibloc

## Key facts

- **NCT ID:** NCT01741519
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741519, "Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01741519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*